other material
confidence high
sentiment positive
materiality 0.75
Roivant reports positive Phase 2 batoclimab data in Graves' disease; response >50%
Roivant Sciences Ltd.
- Initial cohort in Phase 2 trial of batoclimab in Graves' disease showed response rates meaningfully exceeding 50%.
- Batoclimab 680 mg SC achieved up to 87% IgG reduction, mean 81% at 12 weeks; 340 mg showed lower reductions.
- Across clinical parameters, numerically higher responses with 680 mg vs 340 mg, including ATD dose reduction and discontinuation.
- Batoclimab generally well tolerated with no new safety signals observed in the initial data set.
- Immunovant plans to focus future Graves' development on IMVT-1402, with details expected later in 2024.